Business Wire

BIOLOG-ID

12.7.2021 15:56:11 CEST | Business Wire | Press release

Share
Biolog-id Integrates Into the SBS Consultores System to Address the Brazilian Market

Biolog-id, a global service provider of connected healthcare solutions, and SBS Consultores, a software company renowned in the transfusion field, announce a partnership to directly integrate Biolog Transfusion Solution into the SBS Consultores offer.

Well-established on the Brazilian market, SBS Consultores provides a complete system to more than 300 blood banks, blood centers and transfusion agencies to manage all operations and data relating to blood transfusion stages. Committed to giving the best possible user experience, SBS Consultores and biolog-id have worked hand-to-hand to integrate the RFID technology directly into the system, through Biolog Transfusion Solution.

“With a RFID chip placed on the blood bags, all mandatory information is encoded by the biolog-id solution, transforming them into intelligent healthcare products”, explains Philippe Jacquet, Executive Director of Sales EMEA/LATAM at biolog-id. “Combined with software and equipment, Biolog Transfusion Solution offers accurate vein-to-vein visibility, locally and remotely. The technology is now available to Brazilian transfusion healthcare professionals directly through the SBS Consultores system”.

“For several years, SBS Consultores was looking for a solution that would digitally transform labor intensive routines processes, says Carlos Macedo, Partner Director at SBS Consultores. By using the RFID technology, biolog-id offers the capability to improve our ability to automate and secure the blood products supply and to enhance our client’s experience, throughout the transfusion chain. We are very pleased with this collaboration that represents a real progress on the Brazilian market”.

Already deployed in 14 countries, Biolog Transfusion Solution has chosen Brazil as its first market to establish a presence in South America. Currently, some key blood suppliers are under assessment and several installations are expected to be initiated in the coming months.

About biolog-id :
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com

About SBS Consultores:
SBS provides solutions for process automation and information systems directed exclusively to blood banks, blood centers and transfusion agencies, licensed by the ICCBBA to develop applications in the ISBT standard, with more than 40 years of tradition in the Information Technology scenario, and more than 25 years in the hematology and hemotherapy area.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 12:30:00 CET | Press release

Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to achieve in TRDCOMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profileIn COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS2 with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001)3Clinically meaningful reduction in MADRS (≥ 25%) observed in significant number of participants in 25mg arm of both trials with 25% in COMP005 and 39% in COMP006Statistically significant rapid onset from the day following administration maintained at all measured timepoints through Week 6 in both clinical trials in the 25 mg armIn COMP005, participa

BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 12:00:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the

CTC Global Launches GridVista System and Strategic Partnership with Google Cloud and Tapestry to Transform Grid Intelligence17.2.2026 12:00:00 CET | Press release

New technology redefines transmission line intelligence, delivering continuous, high-resolution data across the entire length of the transmission line CTC Global, the world’s leading developer and manufacturer of high-capacity advanced conductors, today announced the launch of the GridVista System. The GridVista System provides utilities with real-time, high-resolution data to optimize grid capacity, prevent outages, reduce wildfire risk, and lower operational costs. With the launch of the GridVista System, CTC is also announcing a deepening of its strategic partnership with Google Cloud and Tapestry—Alphabet’s moonshot for the electric grid. GridVista System’s unprecedented line awareness, paired with Google Cloud and Tapestry’s AI-powered tools, will transform line data into actionable intelligence for the grid. The GridVista System redefines transmission line intelligence by utilizing optical fibers embedded directly within CTC Global’s ACCC Conductor. Unlike legacy technology that

Kingspan Insulation Chooses Expereo to Unify Connectivity and Accelerate Growth Across 90 Global Sites17.2.2026 10:00:00 CET | Press release

Partnership follows Expereo’s recent agreement with Kingspan Light, Air + Water to deliver a fully managed connectivity solution for its worldwide operations Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, announces that Kingspan Insulation, the global manufacturer of premium and high-performance insulation products and systems, has selected Expereo to deliver a fully managed connectivity solution across its worldwide operations. Expereo’s solution enables Kingspan Insulation to consolidate its complex network of disparate ISPs into a single, centralised, fully managed solution - enhancing visibility, compliance, and agility to enable rapid growth and scalability of Kingspan Insulation’s operations. Kingspan Insulation manages a complex WAN environment with 90 sites globally across multiple vendors - which creates significant challenges in terms of efficient connectivity, compliance and security. With the busines

Ohana Development Launches USD 4.1 Billion ‘Manchester City Yas Residences by Ohana’ in Abu Dhabi17.2.2026 09:51:00 CET | Press release

Ohana Development, a leading UAE real estate developer, has officially launched ‘Manchester City Yas Residences by Ohana,’ a USD 4.1 billion gated waterfront community on Yas Canal in Abu Dhabi and Manchester City F.C.’s first branded residential project globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216102386/en/ Manchester City Yas Residences by Ohana (Photo: AETOSWire) The project was launched at Etihad Park in Abu Dhabi, in the presence of Husein Salem, CEO, and Mustafa El Sammak, COO, of Ohana Development as well as Ferran Soriano, CEO of City Football Group. During the event, the Abu Dhabi Real Estate Centre announced the digitisation of Expressions of Interest and booking processes for off-plan purchases through its Madhmoun platform, introducing a new regulated framework in Abu Dhabi. Registrations will operate under ADREC’s direct supervision with mandatory escrow management, strengthening investor prot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye